Fig. 6

Tacle extract exerts anti-MM activity in vivo. A In vivo tumor growth evaluation of subcutaneous AMO xenografts receiving i.p. Tacle (250 mg/kg), or vehicle as control; administrations were performed 5 days a week for a total of two weeks. Average ± SD of the tumor volume for each group is shown; p-values were obtained using two-tailed t-test. *p < 0.05. B Kaplan–Meier curves relative to i.p. Tacle-treated AMO xenografts compared to control xenografts (log-rank test, *p < 0.05). Survival was evaluated from the first day of treatment until death or sacrifice. Percentage of mice alive is shown. WB analysis of C S616 p-DRP1, D Drp1, SREBP1, c-MYC and E pro-Caspase 3 protein levels in tumors retrieved from Tacle- or vehicle-treated mice. GAPDH was used as loading control. F IHC analysis (20 × magnification) of Ki-67 expression in AMO xenografts retrieved from mice, two weeks after Tacle treatment; representative images are reported